Relmada Therapeutics, Inc.

RLMD

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001553643

SEC filings (opens in a new tab)

In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Relmada Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of RLMD: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Of which not filed for Q4 2021	Q4 2021	Change
Holders	87	2	97	+12
Shares	10.0M	36.3K	20.7M	+10.7M (+107.6%)
Value	$262.8M	$950.0K	$467.2M	+$205.3M (+78.4%)

2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held Relmada Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to RLMD in Q4 2021
Institution	Shares	Value	% of portfolio
Ra Capital Management, L.P.	2,000,000	$45.1M	0.79%
BVF Inc	1,647,400	$37.1M	1.35%
Vivo Capital, LLC	882,352	$19.9M	1.20%
Avidity Partners Management LP	731,536	$16.5M	0.35%
Great Point Partners LLC	717,320	$16.2M	3.61%
Sphera Funds Management Ltd.	478,208	$10.8M	1.28%
Acuta Capital Partners, LLC	404,000	$9.10M	3.83%
Logos Global Management LP	400,000	$9.01M	0.93%
Altium Capital Management LP	206,000	$4.64M	1.30%
Ergoteles LLC	91,500	$2.06M	0.08%
apricus wealth, LLC	33,934	$765.0K	0.68%
Walleye Capital LLC	20,819	$469.0K	0.02%
Gsa Capital Partners LLP	17,429	$393.0K	0.05%
Ghisallo Capital Management LLC	15,000	$338.0K	0.02%
Pura Vida Investments, LLC	14,785	$333.0K	0.03%
Golden State Equity Partners	12,325	$278.0K	0.14%
Credit Suisse AG	10,907	$246.0K	0.00%
CM Management, LLC	10,000	$225.0K	0.17%
Knott David M Jr	6,000	$135.0K	0.05%
Byrne Asset Management LLC	5,800	$131.0K	0.08%
Lindbrook Capital, LLC	2,500	$56.0K	0.01%
Aquatic Capital Management LLC	1,000	$23.0K	0.04%
Ensign Peak Advisors, Inc	360	$8.00K	0.00%
Signaturefd, LLC	110	$2.00K	0.00%
Massmutual Trust Co FSB	28	$1.00K	0.00%
FMR LLC	20	$0	0.00%
CWM, LLC	19	$0	0.00%
Quadrant Capital Group LLC	20	$0	0.00%

Sold out (16)

Institutions that held Relmada Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of RLMD in Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Franklin Resources Inc	243,007	$6.37M
Alkeon Capital Management LLC	100,000	$2.62M
Healthcare of Ontario Pension Plan Trust Fund	89,400	$2.34M
State of Wisconsin Investment Board	20,100	$527.0K
Parametric Portfolio Associates LLC	18,117	$475.0K
Jump Financial, LLC	16,900	$443.0K
Belvedere Trading LLC	10,699	$247.0K
Manufacturers Life Insurance Company, The	8,407	$220.0K
Price T Rowe Associates Inc	8,057	$211.0K
DekaBank Deutsche Girozentrale	5,000	$127.0K
Group One Trading, L.P.	2,035	$53.0K
Penserra Capital Management LLC	400	$10.0K
Parallel Advisors, LLC	184	$5.00K
Glen Eagle Advisors, LLC	25	$655
Retirement Group, LLC	5	$0
State of Wyoming	5	$0

Not filed for Q4 2021 yet (2)

Institutions that held Relmada Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding RLMD in Q3 2021 that haven't filed for Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Spotlight Asset Group, Inc.	30,265	$793.0K
Knott David M	6,000	$157.0K